Combination products with tyrosine kinase inhibitors and their use

摘要

H:/dar/Intrwovn/NRPortbI/DCC/DAR/I0262416I.docx-3/06/2016 The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments.